DETERMINING THE MAXIMUM TOLERATED DOSE OF LOW DOSE INTERFERON-ALPHA IN CONJUNCTION WITH NILOTINIB IN PRETREATED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP):